Baker Bros. Advisors LP Igm Biosciences, Inc. Transaction History

Baker Bros. Advisors LP

$7.9 Billion
Q1 2024

A detailed history of Baker Bros. Advisors LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,088,322 shares of IGMS stock, worth $28.1 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares

4,088,322

Previous 3,691,011 10.76%

Holding current value

$28.1 Million

Previous $30.7 Million 28.63%

% of portfolio

0.5%

Previous 0.36%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.68 - $17.36 $3.45 Million - $6.9 Million	397,311 Added 10.76%	4,088,322 $39.5 Million
Q4 2023 Feb 14, 2024	BUY	$3.94 - $8.79 $2.1 Million - $4.69 Million	533,247 Added 16.89%	3,691,011 $30.7 Million
Q3 2023 Nov 14, 2023	BUY	$6.66 - $10.64 $3,689 - $5,894	554 Added 0.02%	3,157,764 $26.4 Million
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $4,908 - $7,756	554 Added 0.02%	3,157,210 $29.1 Million
Q1 2023 May 15, 2023	BUY	$13.74 - $25.76 $7,611 - $14,271	554 Added 0.02%	3,156,656 $43.4 Million

Q1 2021 May 17, 2021	BUY	$71.56 - $121.23 $802,187 - $1.36 Million	11,210 Added 0.36%	3,156,102 $242 Million
Q4 2020 Feb 16, 2021	BUY	$47.41 - $115.03 $21,144 - $51,303	446 Added 0.01%	3,144,892 $278 Million
Q3 2020 Nov 16, 2020	BUY	$43.0 - $84.01 $9,589 - $18,734	223 Added 0.01%	3,144,446 $232 Million
Q2 2020 Aug 14, 2020	BUY	$51.3 - $75.21 $11,439 - $16,771	223 Added 0.01%	3,144,223 $230 Million
Q3 2019 Nov 14, 2019	BUY	$17.75 - $24.3 $55.8 Million - $76.4 Million	3,144,000 New	3,144,000 $55.8 Million

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.5M

Call Options Held

11.1K

Put Options Held

5.1K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $199M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Igm Biosciences, Inc. Transaction History